The generic drug maker Teva Pharmaceuticals agreed Monday to pay $225 million to settle price-fixing charges related to sales of a major cholesterol-lowering drug. The U.S. Department of Justice said the agreement also requires Teva to divest its business making and selling the drug, pravastatin, a generic version of the brand-name medicine Pravachol.

Another generic drug maker, Glenmark Pharmaceuticals, agreed to pay a $30 million criminal penalty and to divest its pravastatin business as well.

  • jeffw@lemmy.worldM
    link
    fedilink
    arrow-up
    2
    arrow-down
    1
    ·
    1 year ago

    I feel like Teva, for a comparatively smaller manufacturer, gets too many headlines about this kind of shit